Oncocyte Q3 2025 Earnings Report

Oncocyte EPS Results

• Actual EPS: -$0.34
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Oncocyte Revenue Results

• Actual Revenue: $0.26 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Oncocyte Announcement Details

• Quarter: Q3 2025
• Date: 11/10/2025
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Oncocyte (NASDAQ:IMDX) (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.

Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows. Its offerings are positioned to support physicians by reducing diagnostic uncertainty, guiding the need for invasive procedures, and helping to prioritize patients for additional testing or treatment. The company pursues clinical validation and regulatory review as part of its path to broader commercial adoption.

Headquartered in the United States, Oncocyte distributes its tests through clinical laboratory networks and strategic partnerships aimed at reaching physicians and healthcare systems. As a publicly listed company on the NASDAQ (IMDX), it concentrates on advancing its diagnostic pipeline, expanding commercial operations, and engaging with payors and clinical stakeholders to integrate its assays into standard oncology care pathways. Information on individual executives and recent leadership changes should be confirmed from the company’s filings and official communications for the most current details.